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Abstract
Background: Genital mycoplasmas colonise up to 80% of sexually mature women and may invade the amniotic
cavity during pregnancy and cause complications. Tetracyclines and fluoroquinolones are contraindicated in
pregnancy and erythromycin is often used to treat patients. However, increasing resistance to common
antimicrobial agents is widely reported. The purpose of this study was to investigate antimicrobial susceptibility
patterns of genital mycoplasmas in pregnant women.
Methods: Self-collected vaginal swabs were obtained from 96 pregnant women attending an antenatal clinic in
Gauteng, South Africa. Specimens were screened with the Mycofast Revolution assay for the presence of
Ureaplasma species and Mycoplasma hominis. The antimicrobial susceptibility to levofloxacin, moxifloxacin,
erythromycin, clindamycin and tetracycline were determined at various breakpoints. A multiplex polymerase chain
reaction assay was used to speciate Ureaplasma positive specimens as either U. parvum or U. urealyticum.
Results: Seventy-six percent (73/96) of specimens contained Ureaplasma spp., while 39.7% (29/73) of Ureaplasma
positive specimens were also positive for M. hominis. Susceptibilities of Ureaplasma spp. to levofloxacin and
moxifloxacin were 59% (26/44) and 98% (43/44) respectively. Mixed isolates (Ureaplasma species and M. hominis)
were highly resistant to erythromycin and tetracycline (both 97% resistance). Resistance of Ureaplasma spp. to
erythromycin was 80% (35/44) and tetracycline resistance was detected in 73% (32/44) of Ureaplasma spp.
Speciation indicated that U. parvum was the predominant Ureaplasma spp. conferring antimicrobial resistance.
Conclusions: Treatment options for genital mycoplasma infections are becoming limited. More elaborative studies
are needed to elucidate the diverse antimicrobial susceptibility patterns found in this study when compared to
similar studies. To prevent complications in pregnant women, the foetus and the neonate, routine screening for the
presence of genital mycoplasmas is recommended. In addition, it is recommended that antimicrobial susceptibility
patterns are determined.
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Background
Mycoplasma hominis and Ureaplasma spp., including U.
parvum and U. urealyticum, are collectively known as
genital mycoplasmas and are found in the vaginal milieu
of up to 80% of pregnant and non-pregnant women [1].
The pathogenesis of genital mycoplasmas is still poorly
understood. Damage related to genital mycoplasma in-
fections might be the result of the induced immune- and
inflammatory responses rather than the direct toxic ef-
fects of mycoplasma cellular components [2]. Mycoplasma
hominis is specifically associated with conditions such as
endometritis [3] and preterm birth [4]. Ureaplasmas are
reported to be more prevalent than other mycoplasmas
in the female urogenital tract, with U. parvum found
more often than U. urealyticum [5]. During pregnancy,
Ureaplasma spp. can cause chorioamnionitis, spontaneous
abortion, stillbirth and preterm delivery [3]. Although the
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pathogenic role of U. urealyticum in urogenital tract infec-
tions is widely recognised [6-8], the role of U. parvum in
these infections is not that well established [7]. Nonethe-
less, U. parvum might be present in bacterial loads leading
to adverse pregnancy outcomes [9] and produce asymp-
tomatic infections of the upper genital tract in women as
frequently as U. urealyticum [7]. Out of the four U. par-
vum serovars (including serovars 1, 3, 6 and 14), serovars 3
and 14 have been isolated in more cases of genital tract
infections than serovars 1 and 6 [10,11]. The greater
virulence reported for U. urealyticum in some condi-
tions might be attributed to its superior capability of ac-
quiring genes horizontally [12].
Genital mycoplasmas display inherent resistance to
beta-lactams and glycopeptides (e.g. vancomycin) because
of the absence of a cell wall [13]. Although macrolides are
often the drugs of choice for treating these infections,
M. hominis is intrinsically resistant to the C14 and C15
macrolides (e.g. erythromycin and azithromycin) [14].
Ureaplasma species also have natural resistance to lin-
cosamides (e.g. clindamycin) [15]. Observed resistance
to macrolides is associated with mutations in the 23S
rRNA gene [16,17], while resistance to tetracyclines is
associated with the presence of the moveable tet(M)
genetic element [18,19].
The administration of antimicrobial agents to pregnant
women with preterm rupture of the membranes (PROM)
may extend the gestation period and decrease the risks of
associated complications and neonatal infections [20]. The
antimicrobial agent of choice should be considered care-
fully, as some agents are teratogens - i.e. the agent can
cause malformation or functional damage to an embryo
or foetus or may have toxic effects on the neonate [21].
Macrolides are often used empirically [22] because of tet-
racyclines and fluoroquinolones being contraindicated in
pregnancy [20,23]. However, the amniotic sac is not effect-
ively penetrated by erythromycin and ureaplasmas are not
eradicated from the vagina or cervix by this agent [13].
Newer macrolides (e.g. azithromycin and clarithromycin)
allow for better tolerability and the once daily dosing
benefit can increase compliance [13,24]. Treatment with
azithromycin is equally successful compared to erythro-
mycin but with fewer side effects [25,26].
To perpetuate the effective use of antimicrobial
agents, the antimicrobial activities of such agents need
to be monitored frequently. The Mycofast Revolution
assay (ELiTech Diagnostic, France) is a commercially avail-
able assay that allows for detection, identification and
antimicrobial-susceptibility testing of genital mycoplasmas
within 48 hours [27]. However, identification with this assay
is limited to M. hominis and the Ureaplasma genus [27].
The speciation of genital mycoplasmas can be achieved by
the use of sensitive and rapid molecular methods, such as
polymerase chain reaction (PCR) assays [28]. Speciation of
bacteria may assist in elucidating the pathogenesis of spe-
cific medical conditions [29]. The purpose of this study was
to investigate the antimicrobial susceptibility patterns of
genital mycoplasmas in pregnant women attending ante-
natal care.
Methods
This investigative study included pregnant women attend-
ing the antenatal and maternal and foetal unit (MAFU)
clinics of a tertiary academic hospital in Pretoria, South
Africa, from October 2012 to January 2013. Patients older
than 18 years were included in the study. All women who
participated gave written informed consent prior to com-
mencement. Ethical approval was obtained from the Stu-
dent Ethics Committee of the Faculty of Health Sciences,
University of Pretoria (protocol number S6/2012) and
preceded experimental work. Experimental work was
conducted at the Department of Medical Microbiology,
University of Pretoria.
Self-collected vaginal swabs (Copan Diagnostics, Inc,
Italy) were obtained and tested for the presence of Urea-
plasma species and M. hominis. Genital mycoplasmas
were identified and enumerated and antimicrobial sus-
ceptibilities were determined with the Mycofast Revolu-
tion assay as indicated by the manufacturer. The swab
was used to seed the UMMt transport medium of which
100 μl were added to the U. urealyticum (UU) and M.
hominis (MH) wells of the Mycofast Revolution Screen-
ing tray. Additionally, 50 μl of MH supplement (S.Mh)
were added to the MH well; the wells were covered with
two drops of sterile mineral oil; and the tray was incu-
bated (Vacutec, South Africa) at 37°C for 24 h. After
24 h of incubation, an orange or red colour change indi-
cated the presence of Ureaplasma species and/or M.
hominis. A yellow colour in the wells marked the absence
of genital mycoplasmas. In the case of a positive screening
test, the remainder of the seeded UMMt that was stored at
4°C to 8°C was used to inoculate the Complement Myco-
fast Revolution tray. One hundred microliters of UMMt
medium were dispensed into wells 1 to 20 and 50 μl of S.
Mh were dispersed into wells 6 and 7. All the wells were
covered with two drops of sterile mineral oil. The tray was
incubated (Vacutec, South Africa) at 37°C ± 1°C for 24 h
(maximum 48 h in all cases) and the presence or absence
of colour changes at defined breakpoints specified on the
inoculation trays indicated resistance or susceptibility to
each antimicrobial agent.
Genital mycoplasma strains were regarded as sensitive
when growth was inhibited by the higher and lower critical
concentrations of the antimicrobial agent. Genital myco-
plasma strains were regarded as resistant when there was
growth at the lower critical concentration of the antimicro-
bial agent but not the higher critical concentration. Strains
were also regarded as resistant when there was growth at
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both the lower and higher critical concentrations of
the antimicrobial agent. The specific breakpoints indi-
cating susceptibility (S) or resistance (R) for Urea-
plasma species were as follows [30]: levofloxacin S ≤2,
R ≥4; moxifloxacin S ≤2; erythromycin S ≤8, R ≥16; and
tetracycline S ≤1, R ≥2. The breakpoints for M. hominis are
as follows: levofloxacin S ≤1, R ≥2; moxifloxacin S ≤0.25;
clindamycin S ≤0.25, R ≥0.5; and tetracycline S ≤4, R ≥8.
A multiplex PCR (mPCR) assay was used to determine
the respective Ureaplasma species detected with the Myco-
fast Revolution assay. This assay was performed as de-
scribed by Stellrecht et al. [3] and was validated with
reference strains ATCC27813 (U. parvum) and ATCC27
619 (U. urealyticum). The multiple-banded antigen (MBA)
gene of Ureaplasma served as the target gene. The ampli-
fied products were subjected to gel electrophoresis at 100 V
for 1 h on a 2% (m/v) MetaPhor agarose gel (Lonza, USA)
in 1X TBE buffer [45 mM Tris-borate (pH 8.0) (Sigma
Chemical co, USA), 1 mM EDTA (Promega, Madison,
USA)]. A 50 kb molecular marker (Fermentas, Thermo Sci-
entific, USA) was used to identify band sizes, which were
403 bp and 448 bp in size for U. parvum and U. urealyti-
cum, respectively [2].
The results were reported as percentages. A two-sample
t-test between proportions was performed to determine
whether there was a significant difference between the re-
sistance of Ureaplasma species and mixed isolates to
erythromycin and tetracycline.
Results
The study population included 96 pregnant African women.
The ages of the women were normally distributed and
ranged from 19 to 43 with a mean and median age of
30. The average gestation period was 25 weeks, ranging
from 10 weeks to 40 weeks. Ureaplasma species were
detected in 76% (73/96) of specimens and 39.7% (29/73)
of Ureaplasma positive specimens were also positive for
M. hominis. Mycoplasma hominis was not detected alone.
The colorimetric assay produced no discordant results; a
slight colour change resulted in an orange colour (a posi-
tive result) and the content of none of the wells looked
turbid, which was indicative of no contamination. To con-
firm results, all the trays were incubated for an additional
24 hours and reread. The growth of Ureaplasma species
and M. hominis at various breakpoints of antimicrobial
agents are displayed in Table 1. Ureaplasma species
and M. hominis in a single specimen were noted as
mixed isolates.
Susceptibilities of 59% (26/44) and 98% (43/44) in the
Ureaplasma species were found for levofloxacin and mox-
ifloxacin respectively. Eighty percent (35/44) of Urea-
plasma strains were resistant to erythromycin, whereas
resistance to tetracycline was detected in 73% (32/44).
Greater resistance was observed for mixed isolates against
erythromycin and tetracycline [both 97% (28/29)] at higher
critical concentrations. The susceptibility patterns of the
mixed isolates to levofloxacin were similar to the cases
where only Ureaplasma species were detected. Mixed iso-
lates were more resistant to moxifloxacin (Figure 1).
The mPCR assay indicated that 95% (42/44) of the
Ureaplasma positive specimens contained only U. parvum,
while 5% (2/44) contained both U. parvum and U. urealyti-
cum. None of the specimens that were positive for Urea-
plasma species had only U. urealyticum present.
Discussion
This study, together with a previously published article
[27], is the first to report antimicrobial susceptibility pat-
terns using the Mycofast Revolution assay from genital
mycoplasmas in this specific setting. The high level of
antimicrobial resistance to erythromycin and tetracycline
that was observed for mixed isolates could be attributed
to M. hominis. The antimicrobial resistance was signifi-
cantly higher than when only Ureaplasma species were
detected (97% vs 80% for erythromycin, p = 0.0396; and
97% vs. 73% for tetracycline, p = 0.0101).
Erythromycin resistance of mixed isolates is comparable
to Domingues et al. [31] and Kechagia and colleagues’
[14] documentation of 90.7% and 100% erythromycin re-
sistance respectively. Tetracycline resistance of mixed iso-
lates was higher (97%) when compared to similar studies
(14% to 57%) [14,22]. Resistance of Ureaplasma species to
erythromycin (80%) is supported by some studies (83%
[14]) but not by others (17.2% [22]). The susceptibility of
Ureaplasma isolates to tetracycline was found to be 27%.
Other studies have reported higher tetracycline suscepti-
bility rates for Ureaplasma isolates, ranging from 81% to
100% [1,14,22]. Most of these studies reported lower tetra-
cycline resistance rates specifically for the species U. urea-
lyticum, which may explain the difference in resistance
Table 1 The distribution (%) of Ureaplasma species and M. hominis at different breakpoints of antimicrobial agents (n = 96)
Levofloxacin Moxifloxacin Erythromycin Clindamycin Tetracycline
11 2 4 0.25 2 8 16 0.25 0.5 1 2 4 8
Sensitive (S)/Resistant (R) S R R S R R R R R R R R R
Ureaplasma species (n = 44) 52 30 11 93 2 70 9 0 100 25 16 2 30
Ureaplasma species and M. hominis (n = 29) 55 28 14 83 10 10 86 0 100 14 28 7 48
1The breakpoints in μg/mL according to the CLSI guidelines [30].
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observed [1,14,31]. The demographics of the participants
in the last-mentioned studies differed in the sense that
one study reported on non-pregnant women of a wider
age range (18–62) [14], while another reported on a group
of pregnant women of gestation >20 weeks [1].
Results of the mPCR assay were that 95% (42/44) of
the Ureaplasma positive specimens contained only U.
parvum, while 5% (2/44) contained both U. parvum and
U. urealyticum. Ureaplasma parvum was the principal
species contributing to antimicrobial resistance. Similar
results were found by Povlsen et al. [32], who investigated
genital mycoplasmas in pregnant women with singleton
pregnancies. These studies reported that approximately
90% of the 280 Ureaplasma positive specimens contained
U. parvum and 3% contained both U. parvum and U.
urealyticum. After speciation of the Ureaplasma positive
specimens, U. parvum strains were discovered to confer
resistance to fluoroquinolones (levofloxacin and moxiflox-
acin) and macrolides (erythromycin). These results are
similar to those of Govender et al. [33], who reported
fluoroquinolone and erythromycin resistance in U. par-
vum strains from South Africa.
Zhu and colleagues [34] reported antimicrobial suscepti-
bilities of 10.65% and 31.27% to levofloxacin for mixed iso-
lates and U. urealyticum respectively. The present study
found genital mycoplasmas to be more susceptible to levo-
floxacin, with susceptibilities of 41% and 42% for Urea-
plasma species and mixed isolates respectively.
The susceptibilities of genital mycoplasmas to anti-
microbial agents differ by geographical region [22]. The
difference in the antimicrobial resistance found in the
present study and in reports from various countries might
be the result of different antimicrobial-usage guidelines,
which would lead to the resistance of bacterial strains to
different antimicrobial groups [14]. Additional variables
contributing to the difference in resistance may include
the population studied, the study period, or the kits used
for specimen processing and analyses [35]. The establish-
ment of common guidelines for the treatment of genital
mycoplasma infections is complex and effective treatment
depends on the antimicrobial susceptibilities of genital
mycoplasmas in a specific region [10,14].
Strategies to preserve the use of current antimicrobial
agents and minimise resistance to such agents may include
the development of: (i) new classes of antimicrobial agents;
(ii) updated derivatives of currently used antimicrobial
agents and; (iii) and the use of two different antimicrobial
agents for treatment instead of one agent [36]. However,
effective resources are required to constantly monitor anti-
microbial susceptibility profiles of such agents to ensure
treatment success and good pregnancy outcomes [10,36].
To circumvent the delays that may be experienced
with the diagnosis of genital mycoplasma infections, the
syndromic management of sexually transmitted infec-
tions (STIs) is a general treatment approach followed in
South Africa. Patients are requested to report symptoms
indicating the presence of an STI; e.g. vaginal discharge
and/or dysuria and/or vulval itching or burning. In the
present study, the symptoms that women reported were
vague and subjective and did not correlate with results.
The women could not definitely distinguish between a
physiological discharge and an unusual vaginal discharge.
Broad-spectrum antimicrobial regimens are used to cover
all potential pathogens and commonly include combining
a cephalosporin (e.g. cefixime) with erythromycin and
metronidazole. A number of studies report that the syn-
dromic approach is not effective in reducing the preva-
lence of curable STIs in asymptomatic patients [37-39].
Our study supports these findings by showing a very high
percentage of resistance to erythromycin in this study
group. Nonetheless, the success of the syndromic man-
agement of STIs relies on up-to-date knowledge of the
infectious agents causing specific syndromes and the anti-




Figure 1 Antimicrobial resistance (%) of Ureaplasma species and M. hominis positive specimens to various antimicrobial agents.
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use of erythromycin in pregnant women has permitted
the surveillance of long-term effects of this antimicro-
bial agent. These include infantile hypertrophic pyloric
stenosis [41], cardiac toxicity [42] and maternal hepato-
toxicity [43]. There is not yet enough data available to
know whether the risks of toxicity in neonates are similar
with newer macrolide antimicrobial agents [13]. If the
price of azithromycin in many countries decreases to an
affordable level, it may potentially replace erythromycin as
a general treatment option in the future. Fluoroquinolones
are classified as category C agents and the use of these
agents in pregnancy is controversial [28]. The treatment
options of genital mycoplasmas in pregnancy therefore re-
main limited.
Monitoring of susceptibility patterns of genital myco-
plasmas may assist with optimising treatment guidelines
and overall improve therapeutic outcomes. The Mycofast
Revolution assay is an easy and effective way of evaluating
the susceptibility of genital mycoplasmas to commonly
used or potential antimicrobial agents [27].
A limitation of the study is that bacterial strains were
not analysed for specific mutations where antimicrobial
resistance was detected. Another limitation may be the
inability of the authors to test for other pathogens, such
as Neisseria gonorrhoeae and Chlamydia trachomatis and
specifically for other Mycoplasma spp., such as Myco-
plasma genitalium. No approved commercially available
diagnostic assay exists for the detection and antimicrobial-
resistance testing of all genital mycoplasma species, in-
cluding M. genitalium. Detection of such species is mainly
by nucleic acid amplification tests (NAATs) [44]. More
studies in the Pretoria region are needed to confirm the
high resistance rates of genital mycoplasmas to common
antimicrobial agents and to determine the specific genetic
elements responsible for resistance. These studies can be
performed in broader study populations, such as non-
pregnant women and HIV-positive women.
Conclusion
Although the fluoroquinolones, especially moxifloxacin,
remain the most effective against genital mycoplasmas,
these agents are restricted to non-pregnant patients. A
discrepancy in antimicrobial susceptibility in different re-
gions emphasises the importance of routine monitoring to
ensure the efficacy of treatment and curb morbidity and
mortality rates.
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